top of page

Rejuve Bio Announces Strategic Collaboration with Aerion Bioscience BV to Revolutionize Lung Cancer Screening

The partnership aims to leverage AI in developing groundbreaking non-invasive screening technologies.

In a groundbreaking move that marks a new frontier in the fight against lung cancer, Rejuve Bio, an innovator in AI biotechnology dedicated to revolutionizing human healthspan, has joined forces with Aerion Bioscience BV, a leader in the early detection of lung cancer. This collaboration brings forth a beacon of hope, leveraging advanced AI to introduce groundbreaking, non-invasive screening technologies that promise not just to detect lung cancer earlier but to redefine the very approach to diagnosis and treatment on a global scale.

Revolutionizing Lung Cancer Detection: Rejuve Bio Partners with Aerion Bioscience

Amidst an era where lung cancer remains the predominant cause of cancer-related mortality worldwide, affecting millions, the imperative for efficient, early detection methodologies is paramount. Rejuve Bio and Aerion Bioscience BV are joining forces to address this challenge head-on. Their collaboration focuses on integrating Rejuve Bio's advanced AI and data analysis capabilities with Aerion Bioscience BV's innovative lung cancer screening platform.

A Leap Forward in Lung Cancer Care: AI Meets Advanced Screening

The goal is to develop a highly sensitive, non-invasive screening method that surpasses current limitations of low-dose CT scans and blood tests. Moreover, the partnership is dedicated to enhancing lung cancer companion diagnostics, aiming to pinpoint patients who will most benefit from specific treatments.

Kennedy Schaal, CEO of Rejuve Bio, emphasized the significance of this partnership, stating, "By combining our strengths in AI biotechnology with Aerion's cutting-edge lung cancer screening technologies, we are poised to make significant strides in the early detection of lung cancer. This collaboration not only represents a milestone in our quest to extend human healthspan but also holds the promise of saving millions of lives through early detection."

Echoing this sentiment, Dr. Axel Schumacher, CEO of Aerion Bioscience, shared his enthusiasm for the joint venture: "The combination of Aerion's innovative 6-protein biomarker panel with Rejuve Bio's neural-symbolic AI signals the dawn of a new epoch in lung cancer screening. Our joint effort is poised to redefine early detection and treatment of lung cancer, significantly enhancing patient outcomes."

Setting New Standards in Early Lung Cancer Detection with AI

This strategic collaboration aims to set new benchmarks in lung cancer screening through the introduction of a cost-effective, non-invasive alternative that minimizes false positives and avoids unnecessary medical interventions. By achieving this, Rejuve Bio and Aerion Bioscience are not just transforming cancer care; they are spearheading a shift towards enhancing human healthspan, ensuring that early and precise detection is within everyone's reach and significantly extending the quality and duration of life.

Join the Fight Against Lung Cancer: Support Rejuve Bio's Crowdfunding Campaign

As we embark on this exciting journey together, Rejuve Bio is thrilled to announce a crowdfunding campaign designed to accelerate our mission and invite everyone to be a part of our shared future. This support will not only fuel our innovative research but also empower Rejuve Bio to bring transformative treatments to market, making a tangible difference in lives worldwide. Rejuve Bio is currently running its Crowd Fund and the company invites everyone to learn more about this unique opportunity by visiting the NetCapital platform. Go to

About Rejuve Bio

Rejuve Bio is an AI biotechnology company dedicated to redefining aging research and extending human healthspan. With a focus on B2B operations, Rejuve Bio employs a multidisciplinary approach, utilizing artificial intelligence, genetics, and cutting-edge data analysis to explore the potential for agelessness. Rejuve Bio mission is to transform the field of longevity research by providing breakthrough therapeutics, drug discovery, and individualized healthspan solutions to improve the quality of life for people all over the world.

About Aerion Bioscience BV

Aerion Bioscience is revolutionizing early lung cancer detection through a simple, non-invasive blood test, leveraging a validated 6-protein biomarker panel to significantly improve survival outcomes for millions. Our mission is to empower doctors to proactively monitor high-risk individuals, transforming the global fight against the most deadly cancer worldwide.

As we move forward on this promising journey, we invite you to join us. Follow our progress, engage with our stories, and be part of a community dedicated to making history in the fight against lung cancer. Together, we are not just chasing a breakthrough; we are redefining the future of global health.

57 views0 comments


bottom of page